Skip to main content
Year archive

Oncopeptides — 2023 filings

All 44 regulatory filings released by Oncopeptides (ONCO) in 2023, sourced directly from the official regulator.

44 Filings
2023 Period
2023 filings (44)
Filing Released Lang
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-11-08 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-11-08 English
Oncopeptides announces the Nomination Committee
AGM Information
2023-10-20 English
Oncopeptides har utsett valberedningen
AGM Information
2023-10-20 Swedish
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2023-09-29 English
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2023-09-29 Swedish
Oncopeptides opts to abandon Type II variation process for Pepaxti to optimize patient and shareholder value
Regulatory Filings
2023-09-28 English
Oncopeptides väljer att avsluta process för typ II-variation för Pepaxti i syfte att optimera patientnytta och aktieägarvärde
Regulatory Filings
2023-09-28 Swedish
CHMP issues positive opinion on Type II variation to extend the therapeutic indication of Pepaxti based on OCEAN trial results
Regulatory Filings
2023-09-14 English
CHMP ger positivt besked om typ II-variation för att utvidga den terapeutiska indikationen av Pepaxti baserat på resultat av OCEAN-studie
Regulatory Filings
2023-09-14 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-08-10 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-08-10 English
Oncopeptides appoints Henrik Bergentoft as Chief Financial Officer
Board/Management Information
2023-08-09 English
Oncopeptides utser Henrik Bergentoft till finanschef
Board/Management Information
2023-08-09 Swedish
Sofia Heigis appointed CEO of Oncopeptides AB (publ)
Board/Management Information
2023-08-07 English
Sofia Heigis utsedd till VD för Oncopeptides AB (publ)
Board/Management Information
2023-08-07 Swedish
Number of shares and votes in Oncopeptides
Share Issue/Capital Change
2023-07-31 English
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2023-07-31 Swedish
Issue and re-purchase of class C shares for shareholder program
Share Issue/Capital Change
2023-06-28 English
Emission och återköp av C-aktier för aktieägarprogram
Share Issue/Capital Change
2023-06-28 Swedish
Holger Lembrér will leave his role as Chief Financial Officer at Oncopeptides
Board/Management Information
2023-06-14 English
Holger Lembrér lämnar rollen som Chief Financial Officer på Oncopeptides
Board/Management Information
2023-06-14 Swedish
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
AGM Information
2023-05-25 English
Kommuniké från årsstämma i Oncopeptides AB (publ)
AGM Information
2023-05-25 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-05-04 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-05-04 English
Oncopeptides issues warrants to utilize the first loan tranche from EIB
Capital/Financing Update
2023-05-03 English
Oncopeptides utfärdar teckningsoptioner för att nyttja första lånetranchen från EIB
Capital/Financing Update
2023-05-03 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-04-25 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-04-25 Swedish
Årsstämma i Oncopeptides AB (publ)
AGM Information
2023-04-21 Swedish
Annual General Meeting in Oncopeptides AB (publ)
AGM Information
2023-04-21 English
Oncopeptides CSO ej längre anhållen
Regulatory Filings
2023-03-10 Swedish
Oncopeptides CSO released from custody
Legal Proceedings Report
2023-03-10 English
Oncopeptides CSO investigated for violation of the Market Abuse Act
Regulatory Filings
2023-03-08 English
Oncopeptides CSO utredes för brott mot marknadsmissbrukslagen
Legal Proceedings Report
2023-03-08 Swedish
Audit Report / Information 2022
Audit Report / Information FY 2022
2023-02-16 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q4 2022
2023-02-16 English
Oncopeptides Chief Financial Officer Holger Lembrer takes office today
Board/Management Information
2023-01-18 English
Oncopeptides Chief Financial Officer Holger Lembrer tillträder idag
Board/Management Information
2023-01-18 Swedish
Oncopeptides appoints Holger Lembrer as Chief Financial Officer
Board/Management Information
2023-01-11 English
Oncopeptides utser Holger Lembrer till Chief Financial Officer
Board/Management Information
2023-01-11 Swedish
Monica Shaw utsedd till vd för Oncopeptides – Jakob Lindberg antar rollen som Chief Scientific Officer
Board/Management Information
2023-01-04 Swedish
Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer
Board/Management Information
2023-01-04 English